Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis

Neurology
Brenda BanwellI Antonijevic

Abstract

Immunomodulatory therapies are widely used in adults with multiple sclerosis (MS) and safety and tolerability is well-established. Although at least 5% of all patients with MS experience the clinical onset of their disease prior to age 18 years, the available literature on safety and tolerability of immunomodulatory therapies for pediatric-onset MS is limited. The authors retrospectively reviewed safety and tolerability of interferon beta-1b (IFNbeta-1b) in a cohort of 43 children and adolescents treated for a mean of 29.2 months (SD 22.3 months). Mean age at start of IFNbeta-1b treatment was 13 years. Eight children were < or =10 years. Most common adverse events included flu-like syndrome (35%), abnormal liver function test (26%), and injection site reaction (21%). No serious or unexpected adverse events were reported. Although data on long-term effects on the maturing organ systems are lacking, the safety profile supports the safety and tolerability of interferon beta-1b (IFNbeta-1b) in children with multiple sclerosis and related diseases. All patients treated with IFNbeta-1b should undergo regular monitoring of liver function.

Citations

Dec 1, 2006·Der Nervenarzt·Peter Rieckmann, Peter Rieckmann
Nov 14, 2008·Journal of Neurology·UNKNOWN Multiple Sclerosis Therapy Consensus Group (MSTCG)R Hohlfeld
Apr 24, 2009·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Angelo GhezziUNKNOWN ITEMS (Immunomodulatory Treatment of Early-onset MS) Group
Apr 15, 2009·Current Treatment Options in Neurology·Krupa Pandey, Fred D Lublin
Aug 13, 2011·Current Treatment Options in Neurology·E Ann Yeh
Dec 12, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Tanuja Chitnis
Jan 1, 2014·Clinical Neurology and Neurosurgery·Silvia N Tenembaum
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Robert A Bermel, Richard A Rudick
Oct 15, 2009·Nature Reviews. Neurology·E Ann YehUNKNOWN US Network of Pediatric Multiple Sclerosis Centers of Excellence
Jan 13, 2011·Nature Reviews. Neurology·Brenda BanwellMarc Tardieu
Nov 24, 2006·The Neurologist·Tanuja Chitnis
Mar 12, 2010·The Neurologist·Sunita Venkateswaran, Brenda Banwell
Aug 21, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Norman PutzkiSebastian Rauer
Oct 1, 2010·Continuum : Lifelong Learning in Neurology·Ellen M Mowry, Emmanuelle Waubant
Apr 14, 2012·Paediatric Drugs·E Ann Yeh
Feb 26, 2010·Annals of Indian Academy of Neurology·Yashma PatelLauren Krupp
Jul 3, 2007·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·A GhezziUNKNOWN Immunomodulatory Treatment of Early-onset MS (ITEMS) Group
Apr 23, 2013·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Mark S FreedmanUNKNOWN Canadian Multiple Sclerosis Working Group
Mar 8, 2007·Expert Review of Neurotherapeutics·Mathias Buttmann, Peter Rieckmann
Mar 8, 2011·Expert Review of Neurotherapeutics·Eluen Ann YehBianca Weinstock-Guttman
May 8, 2007·Expert Opinion on Drug Safety·Marcelo KremenchutzkyCarolina Rush
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Nancy L KuntzUNKNOWN Network of US Pediatric Multiple Sclerosis Centers
Oct 27, 2015·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·J Nicholas Brenton, Brenda L Banwell
Dec 17, 2015·Current Problems in Pediatric and Adolescent Health Care·Sona Narula
Oct 2, 2012·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Carmen Arnal-GarciaCelia Oreja-Guevara
Dec 31, 2011·Journal of the Neurological Sciences·Silvia Tenembaum
Mar 29, 2011·Neurologic Clinics·Tanuja ChitnisEmmanuelle Waubant
Dec 25, 2010·Seminars in Pediatric Neurology·Paul Golumbek
May 18, 2010·Clinical Neurology and Neurosurgery·Silvia N Tenembaum
Jul 11, 2009·Pediatric Neurology·Jennifer E ThannhauserLuanne M Metz
Sep 21, 2007·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Yann MikaeloffUNKNOWN KIDSEP study group of the French Neuropediatric Society
Nov 28, 2007·Developmental Medicine and Child Neurology·Russell C Dale, Sekhar C Pillai
Jun 30, 2006·Mental Retardation and Developmental Disabilities Research Reviews·Amy WaldmanGihan Tennekoon
Oct 5, 2010·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Mikio ZeniyaSyunichi Sadaoka
Aug 23, 2012·Neurological Research·Saeed Talebzadeh NickAlireza Minagar
Mar 7, 2015·La Presse médicale·Sona Narula, Brenda Banwell
Jun 4, 2013·The Journal of Pediatrics·Keith Van Haren, Emmanuelle Waubant
Jul 5, 2007·FEMS Immunology and Medical Microbiology·Zhongyi CongYongli Yu
Jun 9, 2016·Current Neurology and Neuroscience Reports·I-Jun ChouCris S Constantinescu
Jun 18, 2016·Current Treatment Options in Neurology·Marta Simone, Tanuja Chitnis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.